Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

NCT01960348 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT01960348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01960348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2013
Completion date
August 31, 2017
Enrollment
225 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid neuropathies, amyloid neuropathies, familial, amyloidosis, hereditary, amyloidosis, hereditary, transthyretin-related, familial amyloid polyneuropathies, ttr-mediated amyloidosis